Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage I-II colon cancer patients.

Biomedical journal - 1 Feb 2017

Huang Shih-Chiang, Huang Shiu-Feng, Chen Ya-Ting, Chang Yu, Chiu Yu-Ting, Chang Il-Chi, Wu Hong-Dar Isaac, Chen Jinn-Shiun

Abstract excerpt

BACKGROUND: The outcome of colon cancer patients without lymph node metastasis is heterogeneous. Searching for new prognostic markers is warranted. METHODS: One hundred twenty stage I-II colon cancer patients who received complete surgical excision during 1995-2004 were selected for this biomarker study. Immunohistochemical method was used to assess p53, epidermal growth factor receptor, MLH1, and MSH2 status....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Colonic Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Repair

Share to MutL Protein Homolog 1

Share to MutS Homolog 2 Protein

Share to Neoplasm Metastasis

Share to Neoplasm Staging

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 28411881
DOI: 10.1016/j.bj.2017.01.004
PMCID: PMC6138591

Genes

MLH1
MSH2
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage I-II colon cancer patients.PMID 28411881Read ↗

Clinical significance of MLH1/MSH2 for stage II/III sporadic colorectal cancerSemantic proximity Read ↗

Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.Semantic proximity Read ↗

Prognostic and predictive significance of MSI in stages II/III colon cancer.Semantic proximity Read ↗

Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision.Semantic proximity Read ↗

The Effect of Gene Mutations on Metastasis and Overall Survival in Metastatic and Nonmetastatic Colon Cancers.Semantic proximity Read ↗

Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.Semantic proximity Read ↗

Prognostic implications of hMLH1 and p53 immunohistochemical status in right-sided colon cancer.Semantic proximity Read ↗

Differences of protein expression profiles, KRAS and BRAF mutation, and prognosis in right-sided colon, left-sided colon and rectal cancer.Semantic proximity Read ↗

Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trialSemantic proximity Read ↗

MLH1 Deficiency Induces Cetuximab Resistance in Colon Cancer via Her‐2/PI3K/AKT SignalingSemantic proximity Read ↗

Conditional Overall Survival After Diagnosis of Non-Metastatic Colon Cancer: Impact of Laterality, MSI, and KRAS Status.Semantic proximity Read ↗

Mismatch repair proteins immunohistochemical null phenotype in colon medullary carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.